Third, the method of medication should be standardized The dosage of each drug is the best dosage after precise calculation and a lot of experiments and clinical trials, and the efficacy of antiviral drugs is more closely related to the dosage, therefore, patients should not change the dosage of drugs arbitrarily during the process of medication, and the increase in the dosage of the drug does not necessarily improve the efficacy of the drug, but may increase the side effects, and the reduction of dosage arbitrarily not only may not be able to achieve therapeutic effect, but also may sometimes cause Hepatitis reoccurrence or even the emergence of severe hepatitis trend, but also may induce viral drug-resistant mutation, therefore, before the use of medication, doctors and patients should fully communicate, after the use of medication, the patient to improve medication compliance, try to avoid various factors affecting the efficacy of the treatment, in particular, to avoid “three days to fish two days to sunshine net” type of irregular use of medication. Some drugs have special requirements on the use of time should be strictly in accordance with the instructions of the drug, such as entecavir need to be taken on an empty stomach, otherwise it will affect the efficacy. Fourth, the medication course should be standardized Patients receiving antiviral treatment should be prepared for a thought: hepatitis B antiviral treatment is a longer process, only to achieve a certain treatment time, it is possible to achieve more satisfactory results. And this process, each drug is different for each patient, among which, the course of interferon is more clear: ordinary interferon is generally 6-12 months, “long-acting interferon” is 12 months; and the course of nucleoside (acid) analogues should be determined according to the efficacy of China’s 2010 “Chronic Hepatitis B Prevention and Control Guidelines”. China’s 2010 Guidelines for the Prevention and Treatment of Chronic Hepatitis B suggest that, after one year of basic medication, HBeAg-positive (commonly known as “triple positive”) patients should achieve normal liver function, HBV DNA